Literature DB >> 32041739

First EZH2 Inhibitor Approved-for Rare Sarcoma.

.   

Abstract

The FDA has approved tazemetostat for treating epithelioid sarcoma. The drug produced responses in 15% of patients with the disease in a phase II trial, and 67% of the responses lasted at least 6 months. The drug is the first targeted treatment for epithelioid sarcoma. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32041739     DOI： 10.1158/2159-8290.CD-NB2020-006

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  19 in total

1.  SWI/SNF complex-deficient soft tissue neoplasms: An update.

Authors:  Inga-Marie Schaefer; Jason L Hornick
Journal:  Semin Diagn Pathol       Date:  2020-06-05       Impact factor: 3.464

Review 2.  Cancer Epigenetics, Tumor Immunity, and Immunotherapy.

Authors:  Jian Cao; Qin Yan
Journal:  Trends Cancer       Date:  2020-03-31

3.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

4.  Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.

Authors:  Inga-Marie Schaefer; Alyaa Al-Ibraheemi; Xiaohua Qian
Journal:  Am J Clin Pathol       Date:  2021-07-06       Impact factor: 2.493

5.  A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks.

Authors:  Chongze Yuan; Haojie Chen; Shiqi Tu; Hsin-Yi Huang; Yunjian Pan; Xiuqi Gui; Muyu Kuang; Xuxia Shen; Qiang Zheng; Yang Zhang; Chao Cheng; Hui Hong; Xiaoting Tao; Yizhou Peng; Xingxin Yao; Feilong Meng; Hongbin Ji; Zhen Shao; Yihua Sun
Journal:  Genome Biol       Date:  2021-05-17       Impact factor: 13.583

Review 6.  The roles of epigenetics in cancer progression and metastasis.

Authors:  Jocelyn F Chen; Qin Yan
Journal:  Biochem J       Date:  2021-09-17       Impact factor: 3.766

7.  EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.

Authors:  Chen Li; Jiagui Song; Zhengyang Guo; Yueqing Gong; Tengrui Zhang; Jiaqi Huang; Rui Cheng; Xiaotong Yu; Yanfang Li; Li Chen; Xiaojuan Ma; Yan Sun; Yan Wang; Lixiang Xue
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

Review 8.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

9.  Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities.

Authors:  Wai-Kok Choong; Ting-Yi Sung
Journal:  iScience       Date:  2021-05-07

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.